November 20th, 2010
SHARP Shows Benefit for Vytorin in Chronic Kidney Disease
Larry Husten, PHD
The long-awaited SHARP study has turned up positive results for Vytorin (ezetimibe and simvastatin) in a population of patients with chronic kidney disease. Results of SHARP (Study of Heart and Renal Protection) were presented on Saturday at the American Society of Nephrology meeting in Denver and were scheduled to be posted online on the trial’s website. SHARP compared […]
October 1st, 2010
Chronic Kidney Disease and Cardiovascular Risk
Larry Husten, PHD
People with early-stage chronic kidney disease are at elevated risk for cardiovascular disease, according to a new study published in BMJ. Researchers from the U.K. and Iceland followed 17,000 adults in Reykjavik for a median of 24 years and found that people with chronic kidney disease at baseline had significantly elevated risk for cardiovascular events, […]
NEJM Journal Watch — Recent Cardiology Articles- To Lower Stroke Risk in Patients Undergoing Atrial Fibrillation Ablation, Is a Device or a Medication Better?
- Intensive vs. Standard Blood Pressure Lowering in Patients with Diabetes
- Anticoagulation in Patients with Cancer-Associated Pulmonary Embolism: How Long is Long Enough?
- Spironolactone Use After Percutaneous Intervention for Acute Myocardial Infarction
- CRISPR/Cas9 Gene Editing for Transthyretin Cardiomyopathy